Body Mass Index and Polygenic Risk for Alzheimer's Disease Predict Conversion to Alzheimer's Disease.


Journal

The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837

Informations de publication

Date de publication:
13 07 2021
Historique:
received: 13 10 2020
pubmed: 22 4 2021
medline: 21 10 2021
entrez: 21 4 2021
Statut: ppublish

Résumé

Body mass index (BMI) is a risk factor for Alzheimer's disease (AD) although the relationship is complex. Obesity in midlife is associated with increased risk for AD, whereas evidence supports both higher and lower BMI increasing risk for AD in late life. This study examined the influence of individual differences in genetic risk for AD to further clarify the relationship between late-life BMI and conversion to AD. Participants included 52 individuals diagnosed as having mild cognitive impairment (MCI) at baseline who converted to AD within 24 months and 52 matched MCI participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. BMI was measured at baseline. Genetic risk for AD was assessed via genome-wide polygenic risk scores. Conditional logistic regression models were run to determine if BMI and polygenic risk predicted conversion to AD. Results showed an interaction between BMI and genetic risk, such that individuals with lower BMI and higher polygenic risk were more likely to convert to AD relative to individuals with higher BMI. These results remained significant after adjusting for cerebrospinal fluid biomarkers of AD. Exploratory sex-stratified analyses revealed this relationship only remained significant in males. These results show that higher genetic risk in the context of lower BMI predicts conversion to AD in the next 24 months, particularly among males. These findings suggest that genetic risk for AD in the context of lower BMI may serve as a prodromal risk factor for future conversion to AD.

Identifiants

pubmed: 33880516
pii: 6242465
doi: 10.1093/gerona/glab117
pmc: PMC8277084
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1415-1422

Subventions

Organisme : NIA NIH HHS
ID : R01 AG058822
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States
Organisme : NIH HHS
ID : R21AG056921
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG068882
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG056921
Pays : United States
Organisme : NIBIB NIH HHS
Pays : United States
Organisme : CIHR
Pays : Canada

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Arch Neurol. 2009 Sep;66(9):1151-7
pubmed: 19752306
J Nutr Health Aging. 2017;21(10):1259-1267
pubmed: 29188888
Neurosci Biobehav Rev. 2016 Aug;67:102-18
pubmed: 26708713
Maturitas. 2015 Dec;82(4):418-23
pubmed: 26341045
Lancet Neurol. 2019 Feb;18(2):177-184
pubmed: 30663607
Cereb Cortex. 2012 Nov;22(11):2653-61
pubmed: 22169231
Exp Gerontol. 2017 Dec 15;100:45-53
pubmed: 29054536
Neurol Genet. 2020 Sep 08;6(5):e506
pubmed: 33134508
Neurology. 2013 May 7;80(19):1778-83
pubmed: 23390181
Lancet Neurol. 2017 Jun;16(6):465-477
pubmed: 28504110
Neurobiol Aging. 2000 May-Jun;21(3):383-421
pubmed: 10858586
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
J Alzheimers Dis. 2018;65(3):781-791
pubmed: 28697560
Neurology. 2005 Sep 27;65(6):892-7
pubmed: 16186530
Alzheimers Dement. 2016 May;12(5):517-26
pubmed: 26555316
J Cell Mol Med. 2009 Sep;13(9B):3103-9
pubmed: 19438806
Lancet Diabetes Endocrinol. 2015 Jun;3(6):431-436
pubmed: 25866264
Neurobiol Aging. 2016 May;41:200.e13-200.e20
pubmed: 27036079
Neurology. 1996 Jun;46(6):1585-91
pubmed: 8649553
Int J Mol Sci. 2010 Apr 12;11(4):1509-26
pubmed: 20480032
Dement Geriatr Cogn Disord. 2016;41(3-4):172-80
pubmed: 27028129
Biol Psychiatry. 2018 Oct 1;84(7):522-530
pubmed: 29885764
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
Neuropharmacology. 2020 Jul;171:108115
pubmed: 32344008
J Alzheimers Dis. 2019;70(s1):S87-S99
pubmed: 30689574
Alzheimer Dis Assoc Disord. 2014 Apr-Jun;28(2):134-40
pubmed: 24145695
Nat Commun. 2020 Sep 23;11(1):4799
pubmed: 32968074
Arch Intern Med. 2003 Jul 14;163(13):1524-8
pubmed: 12860573
Biochim Biophys Acta. 2000 Jul 26;1502(1):139-44
pubmed: 10899439
Curr Opin Psychiatry. 2018 Mar;31(2):133-139
pubmed: 29324460
Alzheimers Dement (Amst). 2017 Jun 20;8:165-178
pubmed: 28761927
Genome Med. 2016 Nov 1;8(1):104
pubmed: 27799057
Mol Psychiatry. 2014 Jan;19(1):69-75
pubmed: 23089633
Neuroimage. 2010 Jun;51(2):542-54
pubmed: 20197096
Brain Behav Immun. 2014 Nov;42:10-21
pubmed: 24727365
Obes Rev. 2018 Feb;19(2):269-280
pubmed: 29024348
Front Psychiatry. 2018 Apr 17;9:142
pubmed: 29719518
Alzheimers Dement. 2018 May;14(5):601-609
pubmed: 29169013
Alzheimers Dement. 2015 Jul;11(7):792-814
pubmed: 26194313
J Alzheimers Dis. 2017;59(4):1269-1282
pubmed: 28731444
Br J Psychiatry. 1989 Jun;154:801-6
pubmed: 2597886
Ann N Y Acad Sci. 1990;600:405-15; discussion 415-7
pubmed: 1701291
Exp Gerontol. 2004 Nov-Dec;39(11-12):1633-9
pubmed: 15582279
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Nat Genet. 2019 Mar;51(3):414-430
pubmed: 30820047
PLoS Med. 2017 Mar 21;14(3):e1002258
pubmed: 28323831
Am J Med Genet B Neuropsychiatr Genet. 2017 Jan;174(1):5-26
pubmed: 27943641
Arch Gen Psychiatry. 2006 Feb;63(2):168-74
pubmed: 16461860
Mol Psychiatry. 2016 Oct;21(10):1477-82
pubmed: 26857597
Maturitas. 2017 May;99:66-72
pubmed: 28364871
Nat Rev Neurol. 2018 Nov;14(11):653-666
pubmed: 30291317
Neuroimage Clin. 2020;25:102156
pubmed: 31927127
J Gerontol A Biol Sci Med Sci. 2012 Nov;67(11):1140-52
pubmed: 22451474

Auteurs

Jena N Moody (JN)

Department of Psychology, The Ohio State University, Columbus, USA.

Kate E Valerio (KE)

Department of Psychology, The Ohio State University, Columbus, USA.

Alexander N Hasselbach (AN)

Department of Psychology, The Ohio State University, Columbus, USA.

Sarah Prieto (S)

Department of Psychology, The Ohio State University, Columbus, USA.

Mark W Logue (MW)

National Center for PTSD, VA Boston Healthcare System, Massachusetts, USA.
Psychiatry and Biomedical Genetics, Boston University School of Medicine, Massachusetts, USA.

Scott M Hayes (SM)

Department of Psychology, The Ohio State University, Columbus, USA.
Chronic Brain Injury Initiative, The Ohio State University, Columbus, USA.

Jasmeet P Hayes (JP)

Department of Psychology, The Ohio State University, Columbus, USA.
Chronic Brain Injury Initiative, The Ohio State University, Columbus, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH